Elcelyx Therapeutics is developing novel therapeutics based on Gut Sensory Modulation (GSM) science to address unmet needs in the pharmaceutical market. The company's lead proprietary product, NewMet™ has demonstrated clinical proof-of-concept for the treatment of Type 2 diabetes.